dihydromyricetin

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: dihydromyricetin
• 英文别名: ampelopsin；ampeloptin；(-)-Dihydromyricetin；(2S,3S)-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-2,3-dihydrochromen-4-one
• 化学式: C₁₅H₁₂O₈
• 分子量: 320.255
• InChiKey: KJXSIXMJHKAJOD-CABCVRRESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  23
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  148
• 氢给体数：
  6
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  dihydromyricetin 在 碘 、 氧气 、 potassium carbonate 作用下， 以 水 为溶剂， 120.0 ℃ 、200.0 kPa 条件下， 反应 4.0h， 以78.6 mg的产率得到杨梅素
  参考文献：
  名称：

  一种3,5,7,3′,4′,5′-六羟基黄酮的制备方法

  摘要：

  本发明提供一种3,5,7,3',4',5'‑六羟基黄酮的制备方法，以克服现有方法存在的收率低、操作复杂、不适用于工业化生产的问题。以二氢杨梅素为起始原料，通过高温高压、碱性环境及碘催化共同作用发生氧化反应制备二氢杨梅素，一步反应即可获得杨梅素含量大于等于98％的产品，且反应过程中无有机试剂参与，也不存在因反应过程中需补加催化剂而导致安全事故发生的问题，因此本发明方法相对应现有技术操作简单，收率高，绿色环保，适用于工业化生产。

  公开号：

  CN113024502A
• 作为产物：
  描述：

  [2,4,6-tris(methoxymethoxy)phenyl]-[(2S,3S)-3-[3,4,5-tris(methoxymethoxy)phenyl]oxiran-2-yl]methanone 以56%的产率得到
  参考文献：
  名称：

  ONDA, MASAYUKI;LI, SHAOSHUN;LI, XIAN;HARIGAYA, YOSHIHIRO;TAKAHASHI, HIROS+, J. NATUR. PROD., 52,(1989) N, C. 1100-1106

  摘要：

  DOI：

文献信息

• Preparation Of A New Class Of Water-Soluble Ammonium 2,3-Dihydroxy-5-((2R,3R)-3,5,7-Trihydroxy-4-Oxochroman-2-Yl) Phenolates And Their Biological Activity Of Alcohol Elimination
  申请人：JIANG Xianxing

  公开号：US20150203465A1

  公开（公告）日：2015-07-23

  A new class of high water-soluble compound based upon the Hovenia plant, or its herbal extract form known as DHM, and the methods for synthesizing same, to produce anti-alcohol intoxication treatment to alleviate the symptoms of hangover and other over-drinking, binge-drinking related ailments. Such compounds, known as TDHM and PDHM, can reduce the alcohol concentration in the blood, lengthen the waking time, and shorten the period of drowsiness induced after drinking alcohol; they also are proved to have high water solubility and thus are suitable for immediate protection and treatment to persons with alcohol intoxication or hangover and over-drinking.

  一种基于枳椇树（Hovenia）植物或其草药提取物形式（称为二氢杨梅素，DHM）的新型高水溶性化合物及其合成方法，用于生产抗酒精中毒治疗药物，以缓解宿醉和其他过度饮酒、暴饮暴食相关的疾病。这些化合物，称为TDHM和PDHM，可以降低血液中的酒精浓度，延长清醒时间，并缩短饮酒后引起的嗜睡期；它们也被证明具有高水溶性，因此适合对酒精中毒或宿醉和过度饮酒者进行即时保护和治疗
• [EN] SUBSTITUTED IMIDAZO-QUINOLINES AS NLRP3 MODULATORS<br/>[FR] IMIDAZO-QUINOLÉINES SUBSTITUÉES UTILISÉES EN TANT QUE MODULATEURS DE NLRP3
  申请人：INNATE TUMOR IMMUNITY INC

  公开号：WO2018152396A1

  公开（公告）日：2018-08-23

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that modulate (e.g., agonizes or partially agonizes) NLRP3 that are useful, e.g., for treating a condition, disease or disorder in which an increase in NLRP3 signaling may correct a deficiency in innate immune activity (e.g., a condition, disease or disorder associated with an insufficient immune response) that contributes to the pathology and/or symptoms and/ or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions as well as other methods of using and making the same.

  本公开涉及化学实体（例如，化合物或药用可接受盐，和/或水合物，和/或共晶体，和/或该化合物的药物组合），其调节（例如，激动或部分激动）对NLRP3有用，例如，用于治疗增加NLRP3信号可能纠正先天免疫活性缺陷的情况，疾病或紊乱（例如，与免疫反应不足有关的情况，疾病或紊乱），这些情况，疾病或紊乱的病理学和/或症状和/或进展（例如，癌症）的贡献者（例如，人类）中。本公开还涉及组合物以及使用和制备相同的其他方法。
• [EN] COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR TRAITER DES ÉTATS ASSOCIÉS À UNE ACTIVITÉ DE STING
  申请人：IFM DUE INC

  公开号：WO2020252240A1

  公开（公告）日：2020-12-17

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

  本公开涉及抑制（例如，拮抗）干扰素基因激活因子（STING）的化学实体（例如，化合物或药用可接受的盐，和/或水合物，和/或共晶，和/或化合物的药物组合）。所述化学实体是有用的，例如，用于治疗在受试者（例如，人）中增加（例如，过量）STING激活（例如，STING信号传导）有助于病理和/或症状和/或进展的状况、疾病或失调（例如，癌症）。本公开还涉及含有相同成分的药物组合物以及使用和制备相同成分的方法。
• [EN] NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS DE SULFONAMIDE CARBOXAMIDE
  申请人：INFLAZOME LTD

  公开号：WO2019008025A1

  公开（公告）日：2019-01-10

  The present invention relates to compounds of formula (I) wherein Q is selected from O or S; R1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R1 may optionally be substituted; and R2 is a cyclic group substituted at the α-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

  本发明涉及式（I）的化合物，其中Q从O或S中选择；R1是一个非芳香杂环基团，包括至少一个环氮原子，其中R1通过一个环碳原子连接到磺酰脲基团的硫原子，并且R1可以选择性地被取代；R2是在α位被取代的环基团，其中R2也可以选择性地被进一步取代。本发明还涉及这些化合物的盐、溶剂合物和前药，包括这些化合物的药物组合物，以及利用这些化合物治疗和预防医学疾病和疾病的用途，尤其是通过抑制NLRP3。
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：INFLAZOME LTD

  公开号：WO2019068772A1

  公开（公告）日：2019-04-11

  The present invention relates to compounds of formula (I): wherein Q is selected from O or S; R1 is a saturated or unsaturated hydrocarbyl group, wherein the hydrocarbyl group may be straight-chained or branched, or be or include cyclic groups, wherein the hydrocarbyl group may optionally be substituted, and wherein the hydrocarbyl group may optionally include one or more heteroatoms N, O or S in its carbon skeleton; and R2 is a cyclic group substituted at the a-position, wherein R2 may optionally be further substituted. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

  本发明涉及以下式(I)的化合物：其中Q从O或S中选择；R1是饱和或不饱和的烃基团，其中烃基团可以是直链或支链的，或者包括环状基团，其中烃基团可以选择性地被取代，并且其中烃基团的碳骨架中可以选择性地包含一个或多个杂原子N、O或S；以及R2是在α位取代的环状基团，其中R2可以选择性地进一步取代。本发明还涉及这些化合物的盐、溶剂合物和前药，包括这些化合物的药物组合物，以及利用这些化合物治疗和预防医学疾病和疾病的用途，尤其是通过抑制NLRP3。